Human Papillomavirus1 Type 6 L1 protein / Human Papillomavirus1 Type 11 L1 protein / Human Papillomavirus1 Type 16 L1 protein / Human Papillomavirus1 Type 18 L1 protein

Key facts

Invented name
Silgard
Active substance
  • Human Papillomavirus1 Type 6 L1 protein
  • Human Papillomavirus1 Type 11 L1 protein
  • human papillomavirus1 type 16 L1 protein
  • Human Papillomavirus1 Type 18 L1 protein
Therapeutic area
Vaccines
Decision number
P/111/2009
PIP number
Human Papillomavirus1 Type 6 L1 protein / Human Papillomavirus1 Type 11 L1 protein / Human Papillomavirus1 Type 16 L1 protein / Human Papillomavirus1 Type 18 L1 protein
Pharmaceutical form(s)
  • Suspension for injection
  • Suspension for injection in pre-filled syringe
Condition(s) / indication(s)
Infection by Human Papillomavirus
Route(s) of administration
intramuscular use
Contact for public enquiries
Merck Sharp & Dohme (Europe) Inc.
The Netherlands
E-mail: pip.information@merck.com
Tel. +31 4126 63179
Fax +31 4126 62571
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating